G
Gong Tang
Researcher at University of Pittsburgh
Publications - 148
Citations - 13196
Gong Tang is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 34, co-authored 126 publications receiving 11693 citations. Previous affiliations of Gong Tang include Yonsei University & Allegheny General Hospital.
Papers
More filters
Journal ArticleDOI
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik,Steven Shak,Gong Tang,Chungyeul Kim,Joffre B. Baker,Maureen T. Cronin,Frederick L. Baehner,Michael G. Walker,Drew Watson,Taesung Park,William Hiller,Edwin R. Fisher,D. Lawrence Wickerham,John Bryant,Norman Wolmark +14 more
TL;DR: The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.
Journal ArticleDOI
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Soonmyung Paik,Gong Tang,Steven Shak,Chungyeul Kim,Joffre B. Baker,Wanseop Kim,Maureen T. Cronin,Frederick L. Baehner,Drew Watson,John Bryant,Joseph P. Costantino,Charles E. Geyer,D. Lawrence Wickerham,Norman Wolmark +13 more
TL;DR: The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
Journal ArticleDOI
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Eleftherios P. Mamounas,Gong Tang,Bernard Fisher,Soonmyung Paik,Steven Shak,Joseph P. Costantino,Drew Watson,Charles E. Geyer,D. Lawrence Wickerham,Norman Wolmark +9 more
TL;DR: A significant association exists between RS and risk for locoregional recurrence (LRR) in patients with node-negative, ER-positive breast cancer from two National Surgical Adjuvant Breast and Bowel Project trials and in multivariate analysis, RS was an independent significant predictor of LRR along with age and type of initial treatment.
Journal ArticleDOI
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear,Gong Tang,Priya Rastogi,Charles E. Geyer,André Robidoux,James N. Atkins,Luis Baez-Diaz,Adam Brufsky,Rita S. Mehta,Louis Fehrenbacher,James A. Young,Francis M. Senecal,Rakesh Gaur,Richard G. Margolese,Paul T. Adams,Howard M. Gross,Joseph P. Costantino,Sandra M. Swain,Eleftherios P. Mamounas,Norman Wolmark +19 more
TL;DR: The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response, which was the primary end point of this study.
Journal ArticleDOI
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
André Robidoux,Gong Tang,Priya Rastogi,Charles E. Geyer,Catherine A. Azar,James N. Atkins,Louis Fehrenbacher,Harry D. Bear,Louis Baez-Diaz,Shakir Sarwar,Richard G. Margolese,William B. Farrar,Adam Brufsky,Henry R. Shibata,Hanna Bandos,Soonmyung Paik,Joseph P. Costantino,Sandra M. Swain,Eleftherios P. Mamounas,Norman Wolmark +19 more
TL;DR: Substitution of lapatinib for trastuzumab in combination with chemotherapy resulted in similar high percentages of pathological complete response than single-agent HER2-directed therapy; these findings are consistent with results from other studies.